TEXAS BIOTECHNOLOGY CORP /DE/
S-8, 1997-05-19
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: TRIANGLE BANCORP INC, 8-K, 1997-05-19
Next: TEXAS BIOTECHNOLOGY CORP /DE/, S-8, 1997-05-19



<PAGE>   1
     As filed with the Securities and Exchange Commission on May 19, 1997.

                                                           Registration No. 333-
================================================================================

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                 -------------

                                    FORM S-8
                             REGISTRATION STATEMENT
                        Under THE SECURITIES ACT OF 1933

                                 -------------

                        TEXAS BIOTECHNOLOGY CORPORATION
             (Exact name of registrant as specified in its charter)

                                 -------------

                DELAWARE                                    13-3532643
      (State or Other Jurisdiction                       (I.R.S. Employer
    of Incorporation or Organization)                    Identification No.)

                         7000 FANNIN STREET, SUITE 1920
                              HOUSTON, TEXAS 77030
   (Address, including Zip Code, of Registrant's Principal Executive Offices)

                                 -------------

              TEXAS BIOTECHNOLOGY CORPORATION AMENDED AND RESTATED
                             1995 STOCK OPTION PLAN

                                 -------------

  Name, Address and Telephone                       Copy of communications to:
  Number of Agent for Service:

      DAVID B. MCWILLIAMS                                ROBERT G. REEDY
TEXAS BIOTECHNOLOGY CORPORATION                      PORTER & HEDGES, L.L.P.
7000 FANNIN STREET, SUITE 1920                  700 LOUISIANA STREET, SUITE 3500
      HOUSTON, TEXAS 77030                          HOUSTON, TEXAS 77002-2370
         (713) 796-8822                                   (713) 226-0600

                        CALCULATION OF REGISTRATION FEE

<TABLE>
<CAPTION>
===================================================================================================================================
                                                                   PROPOSED MAXIMUM            PROPOSED                            
                                                AMOUNT TO              OFFERING            MAXIMUM AGGREGATE         AMOUNT OF     
TITLE OF SECURITIES TO BE REGISTERED        BE REGISTERED (1)    PRICE PER SHARE (2)      OFFERING PRICE (2)   REGISTRATION FEE (2)
- -----------------------------------------------------------------------------------------------------------------------------------
  <S>                                           <C>                    <C>                    <C>                     <C>          
Common Stock, par value $.005 per share         1,000,000              $4.34375               $4,343,750              $1,498       
===================================================================================================================================
</TABLE>

(1)   Pursuant to Rule 416(a), also registered hereunder is an indeterminate
      number of shares of Common Stock issuable as a result of the
      anti-dilution provisions of the Plan.

(2)   Pursuant to Rule 457(c) and (h), the registration fee is computed upon
      the basis of the average of the high and low prices, $4.34375 per share,
      at which the Common Stock sold on the American Stock Exchange as reported
      on the consolidated reporting system on May 14, 1997.
<PAGE>   2
This registration statement registers additional securities related to the
Texas Biotechnology Corporation Amended and Restated 1995 Stock Option Plan
(the "1995 Plan") of the same class as other securities for which a
registration statement on Form S-8 no. 33-93368 (the "Previous Registration
Statement"), has been previously filed.  The Previous Registration Statement
covered an aggregate of 1,000,000 shares of Common Stock, and this registration
statement increases the shares covered by the 1995 Plan by 1,000,000 shares.
Pursuant to General Instruction E of Form S-8, the contents of the Previous
Registration Statement are hereby incorporated by reference.


ITEM 8.          EXHIBITS


            Exhibit                        Description
                     
              5.1                Opinion of Porter & Hedges, L.L.P.
                     
              23.1               Consent of KPMG Peat Marwick LLP
                     
              23.2               Consent of Porter & Hedges, L.L.P.
                                 (included in Exhibit 5.1 Opinion)
                     
              24.1               Power of Attorney (included on the
                                 signature page hereto)
<PAGE>   3
                                   SIGNATURES

         Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets
all the requirements for filing on Form S-8 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized in the City of Houston, State of Texas, on May 19, 1997.

                                                 TEXAS BIOTECHNOLOGY CORPORATION

                                        By:        /s/ Stephen L. Mueller
                                           -------------------------------------
                                           STEPHEN L. MUELLER                 
                                           VICE PRESIDENT OF ADMINISTRATION   
                                           TREASURER AND SECRETARY            
                                           (PRINCIPAL FINANCIAL AND ACCOUNTING
                                           OFFICER)

                               POWER OF ATTORNEY

         Each of the undersigned hereby appoints David B. McWilliams and
Stephen L. Mueller and each of them (with full power to act alone), as attorney
and agents for the undersigned, with full power of substitution, for and in the
name, place and stead of the undersigned, to sign and file with the Securities
and Exchange Commission under the Securities Act of 1933 any and all amendments
and exhibits to this Registration Statement and any and all applications,
instruments and other documents to be filed with the Securities and Exchange
Commission pertaining to the registration of the securities covered hereby,
with full power and authority to do and perform any and all acts and things
whatsoever requisite or desirable.

         Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities indicated on the 19th day of May, 1997.

<TABLE>
<CAPTION>
                 SIGNATURE                                             TITLE
                 ---------                                             -----
<S>                                               <C>
          /s/ John M. Pietruski                         Chairman of the Board of Directors
- ------------------------------------------
             JOHN M. PIETRUSKI

          /s/ David B. McWilliams                 Director, President and Chief Executive Officer
- ------------------------------------------                 (Principal Executive Officer)
            DAVID B. MCWILLIAMS                                                         

          /s/ Richard A.F. Dixon                      Director and Vice President of Research
- ------------------------------------------
            RICHARD A.F. DIXON

          /s/ Stephen L. Mueller                         Vice President of Administration
- ------------------------------------------                    Treasurer and Secretary          
            STEPHEN L. MUELLER                     (Principal Financial and Accounting Officer)
                                                                                               
           /s/ Frank C. Carlucci                                     Director
- ------------------------------------------
             FRANK C. CARLUCCI

                                                                     Director
- ------------------------------------------
              RITA R. COLWELL

         /s/ Robert J. Cruikshank                                    Director
- ------------------------------------------
           ROBERT J. CRUIKSHANK

          /s/ James T. Willerson                                     Director
- ------------------------------------------
            JAMES T. WILLERSON

           /s/ James A. Thomson                                      Director
- ------------------------------------------
             JAMES A. THOMSON
</TABLE>





<PAGE>   4
                               INDEX TO EXHIBITS




<TABLE>
<CAPTION>
     Number                       Description
     ------                       -----------
       <S>           <C>
        5.1          Opinion of Porter & Hedges, L.L.P.

       23.1          Consent of KPMG Peat Marwick LLP

       23.2          Consent of Porter & Hedges, L.L.P. (included in Exhibit
                     5.1 Opinion)

       24.1          Power of Attorney (included on the signature page hereto)
</TABLE>






<PAGE>   1

                                                                     EXHIBIT 5.1


                          [PORTER & HEDGES LETTERHEAD]


                                  May 12, 1997

Texas Biotechnology Corporation
7000 Fannin, Suite 1920
Houston, Texas 77030

Ladies and Gentlemen:

        We have acted as counsel to Texas Biotechnology Corporation, a Delaware
corporation (the "Company"), in connection with the preparation and filing of a
Registration Statement on Form S-8 (the "Registration Statement") with the
Securities and Exchange Commission pursuant to the Securities Act of 1933, as
amended. The Registration Statement relates to an aggregate of 1,000,000 shares
(the "Shares") of the Company's common stock, par value $.005 per share. The
Shares are subject to issuance on the exercise of options granted, or to be
granted, or the vesting of shares of restricted stock or phantom stock granted
and on the granting of stock bonuses under the Company's Amended and Restated
1995 Stock Option Plan (the "Plan").

        We have examined such corporate records, documents, instruments and
certificates of the Company and have received such representations from the
officers and directors of the Company and have reviewed such questions of law
as we have deemed necessary, relevant or appropriate to enable us to render the
opinion expressed herein. In such examination, we have assumed the genuineness
of all signatures and the authenticity of all documents, instruments, records
and certificates submitted to us as originals.

        Based on such examination and review and on representations made to us
by the officers and directors of the Company, we are of the opinion that the
Shares have been duly and validly authorized and will, on issuance and delivery
as contemplated in the Plan, be validly issued, fully paid and nonassessable
shares of the Company's capital stock.

        This firm consents to the filing of this opinion as an exhibit to the
Registration Statement.

                                Very truly yours,

                                /s/PORTER & HEDGES, L.L.P.

                                Porter & Hedges, L.L.P.

<PAGE>   1
                                                                   EXHIBIT 23.1



                        CONSENT OF INDEPENDENT AUDITORS'


The Board of Directors
Texas Biotechnology Corporation:

We hereby consent to the use of our report incorporated herein by reference
dated February 21, 1997, related to the consolidated financial statements of
Texas Biotechnology Corporation and subsidiary as of December 31, 1996 and
1995, for each of the years in the three-year period ended December 31, 1996,
and for the period from August 2, 1989 (date of incorporation) to December 31,
1996.

                                                /s/ KPMG Peat Marwick LLP


Houston, Texas
May 13, 1997


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission